04:45 , Feb 22, 2019 |  BC Innovations  |  Targets & Mechanisms

Solid checkpoint for CARs

PD-L1 family member B7-H3 could put CAR T cells in play for a slew of difficult-to-treat solid tumors, including pediatric cancers that lack targeted therapies, according to a pair of preclinical studies published this year....
00:56 , Jan 25, 2019 |  BC Innovations  |  Product R&D

Rubius turns immunotherapy red

As it gets ready to bring the first engineered red blood cell therapy into the clinic, Rubius Therapeutics Inc. is working up the next generation of RBC therapies to mimic immune cell interactions. The company...
18:57 , Jan 11, 2019 |  BC Week In Review  |  Company News

Medigene licenses co-stimulator from Helmholtz to overcome checkpoint blockade with TCRs

Medigene AG (Xetra:MDG1) received exclusive, worldwide rights to a chimeric co-stimulatory receptor from Helmholtz Zentrum München (Neuherberg, Germany) for therapeutic and diagnostic use in TCR therapies and DC vaccines. Helmholtz designed the co-stimulator, a fusion...
19:26 , Dec 21, 2018 |  BC Week In Review  |  Company News

Amgen adds stroma-targeted therapy via Molecular Partners deal

Through a deal with Molecular Partners AG (SIX:MOLN) giving it rights to programs targeting the tumor stroma, Amgen Inc. (NASDAQ:AMGN) will expand its immuno-oncology toolbox beyond tumor antigen-targeted therapies. On Dec. 19, Amgen received exclusive,...
20:21 , Dec 19, 2018 |  BC Extra  |  Company News

Amgen adds stroma-targeted therapy via Molecular Partners deal

Through a deal with Molecular Partners AG (SIX:MOLN) giving it rights to programs targeting the tumor stroma, Amgen Inc. (NASDAQ:AMGN) will expand its immuno-oncology toolbox beyond tumor antigen-targeted therapies. On Wednesday, Amgen received exclusive, worldwide...
05:02 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Souped-up CARs at ASH 2018

Rather than searching for new antigens, makers of the latest generation of CAR therapies are focusing on the CARs themselves by designing more sophisticated methods of targeting multiple antigens, controlling cytotoxicity and enhancing tumor-homing. BioCentury’s...
19:32 , Sep 7, 2018 |  BC Week In Review  |  Company News

Atara partners with Moffitt Cancer Center to develop CAR T therapies

Atara Biotherapeutics Inc. (NASDAQ:ATRA) partnered with H. Lee Moffitt Cancer Center and Research Institute (Tampa, Fla.) to develop multi‑targeted CAR T immunotherapies to treat cancers with diverse cell types that often become resistant to treatment,...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
11:06 , Sep 8, 2017 |  BioCentury  |  Product Development

Maximizing neoantigens

In conjunction with raising $55 million in a series B round on Friday, Replimune Group Inc. unveiled details of its Immulytic oncolytic virus platform, including next-generation constructs that underpin the company’s strategy for creating multimodal...
00:53 , Jun 8, 2017 |  BC Innovations  |  Emerging Company Profile

Killer expansion

CytoSen Therapeutics Inc. 's nanoparticle technology expands and activates patient-derived NK cells ex vivo with fewer safety risks and manufacturing challenges than other expansion protocols. Unlike T cells, which mount highly specific immune responses to...